Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for Avidity Biosciences (RNA) over the last 6 years, with Dec 2024 value amounting to $98.0 million.

  • Avidity Biosciences' Total Current Liabilities rose 86.00% to $169.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.9 million, marking a year-over-year increase of 86.00%. This contributed to the annual value of $98.0 million for FY2024, which is 21.49% up from last year.
  • Per Avidity Biosciences' latest filing, its Total Current Liabilities stood at $98.0 million for FY2024, which was up 21.49% from $80.7 million recorded in FY2023.
  • In the past 5 years, Avidity Biosciences' Total Current Liabilities ranged from a high of $98.0 million in FY2024 and a low of $14.6 million during FY2020.
  • Moreover, its 3-year median value for Total Current Liabilities was $80.7 million (2023), whereas its average is $76.9 million.
  • Data for Avidity Biosciences' Total Current Liabilities shows a peak YoY spiked of 103.32% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Avidity Biosciences' Total Current Liabilities stood at $14.6 million in 2020, then surged by 103.32% to $29.7 million in 2021, then skyrocketed by 75.02% to $51.9 million in 2022, then soared by 55.43% to $80.7 million in 2023, then increased by 21.49% to $98.0 million in 2024.